Triad Life Sciences

Triad Life Sciences is a regenerative medicine company that develops and commercializes biologically active tissue products for advanced wound care and surgical applications. The company's core technology, InnovaMatrix, is a next-generation extracellular matrix (ECM) platform derived from porcine placenta, designed to provide a scaffold for host cell remodeling and tissue regeneration. Their product portfolio addresses complex clinical challenges such as diabetic foot ulcers, venous leg ulcers, and chronic wounds. In 2022, the company was acquired by Convatec to strengthen its position in the global wound biologics market. The acquisition allowed Convatec to enter the rapidly growing wound biologics segment with a unique, high-margin product line.